Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Teva settles patent litigation with Neos; gets rights to market generic Cotempla XR

Executive Summary

As part of a patent litigation settlement, Neos Therapeutics Inc. granted Teva Pharmaceuticals USA Inc. rights to manufacture and market a generic form of its Cotempla XR-ODT. Under the agreement, Teva may begin to manufacture and market the drug beginning on July 1, 2026 or earlier.
Deal Industry
  • Pharmaceuticals
    • Drug Delivery
      • Controlled Release
    • Generic Drugs
Deal Status
  • Final
Deal Type
  • Alliance
    • Marketing-Licensing

Related Companies